Verona Pharma PLC American Depositary Share (VRNA) Expected to Announce Quarterly Earnings on Monday

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) is anticipated to post its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect Verona Pharma PLC American Depositary Share to post earnings of $0.17 per share and revenue of $86.7240 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 3, 2025 at 9:00 AM ET.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last posted its earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%.The company had revenue of $103.14 million for the quarter, compared to analysts’ expectations of $90.41 million. On average, analysts expect Verona Pharma PLC American Depositary Share to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Verona Pharma PLC American Depositary Share Price Performance

Shares of NASDAQ:VRNA opened at $106.91 on Monday. The stock’s 50-day moving average is $106.41 and its 200 day moving average is $92.86. The company has a market cap of $9.21 billion, a PE ratio of -107.99 and a beta of 0.05. The company has a debt-to-equity ratio of 0.87, a current ratio of 10.71 and a quick ratio of 10.54. Verona Pharma PLC American Depositary Share has a 1 year low of $31.09 and a 1 year high of $106.93.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on VRNA. Jefferies Financial Group reissued a “hold” rating and set a $107.00 target price (down from $140.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Wednesday, July 9th. Cowen cut shares of Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a report on Wednesday, July 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 price objective on shares of Verona Pharma PLC American Depositary Share in a research report on Wednesday, October 8th. Wolfe Research lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Finally, TD Cowen lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 9th. Two research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Verona Pharma PLC American Depositary Share currently has an average rating of “Hold” and a consensus target price of $109.00.

Insider Activity

In related news, Director Vikas Sinha sold 4,328 shares of Verona Pharma PLC American Depositary Share stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $56,869.92. Following the completion of the transaction, the director directly owned 94,112 shares of the company’s stock, valued at $1,236,631.68. This trade represents a 4.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David R. Ebsworth sold 1,904 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $25,018.56. Following the sale, the director directly owned 880,499 shares in the company, valued at $11,569,756.86. The trade was a 0.22% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 540,584 shares of company stock worth $7,103,274. 4.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Verona Pharma PLC American Depositary Share

Large investors have recently made changes to their positions in the business. Royal Bank of Canada boosted its position in shares of Verona Pharma PLC American Depositary Share by 43.3% in the 1st quarter. Royal Bank of Canada now owns 9,719 shares of the company’s stock worth $617,000 after purchasing an additional 2,938 shares in the last quarter. NewEdge Advisors LLC bought a new stake in Verona Pharma PLC American Depositary Share in the first quarter worth $58,000. Goldman Sachs Group Inc. grew its stake in shares of Verona Pharma PLC American Depositary Share by 274.5% in the first quarter. Goldman Sachs Group Inc. now owns 1,041,408 shares of the company’s stock worth $66,119,000 after acquiring an additional 763,353 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Verona Pharma PLC American Depositary Share by 44.2% during the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock valued at $40,000 after acquiring an additional 193 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Verona Pharma PLC American Depositary Share during the first quarter valued at $48,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.